Identification of Dmt-D-Lys-Phe-Phe-OH as a highly antinociceptive tetrapeptide metabolite of the opioid-neurotensin hybrid peptide PK20

Patrycja Kleczkowska, Engin Bojnik, Anna LeAniak, Piotr Kosson, Isabelle Van Den Eynde, Steven Ballet, S. Benyhe, Dirk Tourwe, Andrzej W. Lipkowski

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Recently, we presented a novel compound (PK20, Dmt-D-Lys-Phe-Phe-Lys-Lys-Pro-Phe-Tle-Leu-OH) that targets single entity opioid and neurotensin pharmacophores. This endomorphin-2-like opioid peptide was introduced as a highly active analgesic because it elicited a strong dose- and time-dependent antinociceptive response when administered centrally and peripherally. Its pain-relieving activity was observed as rapidly as 5 min after drug injection. Such promising results led us to perform further studies, such as determining the resistance to enzymatic degradation, which resulted in obtaining a very stable opioid pharmacore PK20 metabolite. Methods: The synthesis of PK20 and its N-terminal tetrapeptide fragment has been accomplished using solid phase peptide chemistry. The biological stability of peptides has been measured in human serum and analyzed by HPLC/MS. Peptides were pharmacologically characterized in in vitro MOP and DOP receptor binding as well as [35S]GTP?S receptor binding assays. Antinociceptive properties of compounds were measured by in vivo assays in C57Bl6 mice after intravenous or intrathecal applications. Results: Dmt-D-Lys-Phe-Phe-OH (PK20M), an N-terminal tetrapeptide metabolite of the opioid-neurotensin hybrid peptide PK20, is characterized by a long duration of action, as demonstrated by a preserved, long-lasting analgesic effect even 2 h post-injection (average % MPE = 69.33). In rat brain membranes, PK20M efficiently displaced both the MOP and DOP receptor selective radioprobes [3H]DAMGO and [3H]DIDI (pKi of 9.52 and 7.86, respectively) and potently stimulated [35S]GTP?S binding, proving full agonism at both receptor types. In the [35S]GTP?S assay, which measured the agonist-mediated G protein activation, PK20M together with PK20 and Met-enkephalin were potent stimulators of the regulatory G proteins. The relative affinities of PK20M for the ? and receptor subtypes revealed ?-receptor selectivity. Conclusion: The novel MOP receptor selective metabolite has been shown to possess opioid subtype receptor selectivity, high potency, and effective analgesic activities as measured in various bioassays.

Original languageEnglish
Pages (from-to)836-846
Number of pages11
JournalPharmacological Reports
Volume65
Issue number4
Publication statusPublished - 2013

Fingerprint

Neurotensin
Opioid Analgesics
Guanosine Triphosphate
Analgesics
Peptides
GTP-Binding Proteins
Ala(2)-MePhe(4)-Gly(5)-enkephalin
Methionine Enkephalin
Injections
Opioid Peptides
Opioid Receptors
Biological Assay
High Pressure Liquid Chromatography
Pain
Membranes
phenylalanyl-lysyl-phenylalanine
Brain
Serum
Pharmaceutical Preparations

Keywords

  • [35S]GTP?S
  • Antinociception
  • In vivo analgesia
  • Opioid receptor binding
  • PK20 metabolite

ASJC Scopus subject areas

  • Pharmacology

Cite this

Kleczkowska, P., Bojnik, E., LeAniak, A., Kosson, P., Van Den Eynde, I., Ballet, S., ... Lipkowski, A. W. (2013). Identification of Dmt-D-Lys-Phe-Phe-OH as a highly antinociceptive tetrapeptide metabolite of the opioid-neurotensin hybrid peptide PK20. Pharmacological Reports, 65(4), 836-846.

Identification of Dmt-D-Lys-Phe-Phe-OH as a highly antinociceptive tetrapeptide metabolite of the opioid-neurotensin hybrid peptide PK20. / Kleczkowska, Patrycja; Bojnik, Engin; LeAniak, Anna; Kosson, Piotr; Van Den Eynde, Isabelle; Ballet, Steven; Benyhe, S.; Tourwe, Dirk; Lipkowski, Andrzej W.

In: Pharmacological Reports, Vol. 65, No. 4, 2013, p. 836-846.

Research output: Contribution to journalArticle

Kleczkowska, P, Bojnik, E, LeAniak, A, Kosson, P, Van Den Eynde, I, Ballet, S, Benyhe, S, Tourwe, D & Lipkowski, AW 2013, 'Identification of Dmt-D-Lys-Phe-Phe-OH as a highly antinociceptive tetrapeptide metabolite of the opioid-neurotensin hybrid peptide PK20', Pharmacological Reports, vol. 65, no. 4, pp. 836-846.
Kleczkowska, Patrycja ; Bojnik, Engin ; LeAniak, Anna ; Kosson, Piotr ; Van Den Eynde, Isabelle ; Ballet, Steven ; Benyhe, S. ; Tourwe, Dirk ; Lipkowski, Andrzej W. / Identification of Dmt-D-Lys-Phe-Phe-OH as a highly antinociceptive tetrapeptide metabolite of the opioid-neurotensin hybrid peptide PK20. In: Pharmacological Reports. 2013 ; Vol. 65, No. 4. pp. 836-846.
@article{054afae0b48049d5b8f1992b541e831d,
title = "Identification of Dmt-D-Lys-Phe-Phe-OH as a highly antinociceptive tetrapeptide metabolite of the opioid-neurotensin hybrid peptide PK20",
abstract = "Background: Recently, we presented a novel compound (PK20, Dmt-D-Lys-Phe-Phe-Lys-Lys-Pro-Phe-Tle-Leu-OH) that targets single entity opioid and neurotensin pharmacophores. This endomorphin-2-like opioid peptide was introduced as a highly active analgesic because it elicited a strong dose- and time-dependent antinociceptive response when administered centrally and peripherally. Its pain-relieving activity was observed as rapidly as 5 min after drug injection. Such promising results led us to perform further studies, such as determining the resistance to enzymatic degradation, which resulted in obtaining a very stable opioid pharmacore PK20 metabolite. Methods: The synthesis of PK20 and its N-terminal tetrapeptide fragment has been accomplished using solid phase peptide chemistry. The biological stability of peptides has been measured in human serum and analyzed by HPLC/MS. Peptides were pharmacologically characterized in in vitro MOP and DOP receptor binding as well as [35S]GTP?S receptor binding assays. Antinociceptive properties of compounds were measured by in vivo assays in C57Bl6 mice after intravenous or intrathecal applications. Results: Dmt-D-Lys-Phe-Phe-OH (PK20M), an N-terminal tetrapeptide metabolite of the opioid-neurotensin hybrid peptide PK20, is characterized by a long duration of action, as demonstrated by a preserved, long-lasting analgesic effect even 2 h post-injection (average {\%} MPE = 69.33). In rat brain membranes, PK20M efficiently displaced both the MOP and DOP receptor selective radioprobes [3H]DAMGO and [3H]DIDI (pKi of 9.52 and 7.86, respectively) and potently stimulated [35S]GTP?S binding, proving full agonism at both receptor types. In the [35S]GTP?S assay, which measured the agonist-mediated G protein activation, PK20M together with PK20 and Met-enkephalin were potent stimulators of the regulatory G proteins. The relative affinities of PK20M for the ? and receptor subtypes revealed ?-receptor selectivity. Conclusion: The novel MOP receptor selective metabolite has been shown to possess opioid subtype receptor selectivity, high potency, and effective analgesic activities as measured in various bioassays.",
keywords = "[35S]GTP?S, Antinociception, In vivo analgesia, Opioid receptor binding, PK20 metabolite",
author = "Patrycja Kleczkowska and Engin Bojnik and Anna LeAniak and Piotr Kosson and {Van Den Eynde}, Isabelle and Steven Ballet and S. Benyhe and Dirk Tourwe and Lipkowski, {Andrzej W.}",
year = "2013",
language = "English",
volume = "65",
pages = "836--846",
journal = "Pharmacological Reports",
issn = "1734-1140",
publisher = "Polish Academy of Sciences Publishing House",
number = "4",

}

TY - JOUR

T1 - Identification of Dmt-D-Lys-Phe-Phe-OH as a highly antinociceptive tetrapeptide metabolite of the opioid-neurotensin hybrid peptide PK20

AU - Kleczkowska, Patrycja

AU - Bojnik, Engin

AU - LeAniak, Anna

AU - Kosson, Piotr

AU - Van Den Eynde, Isabelle

AU - Ballet, Steven

AU - Benyhe, S.

AU - Tourwe, Dirk

AU - Lipkowski, Andrzej W.

PY - 2013

Y1 - 2013

N2 - Background: Recently, we presented a novel compound (PK20, Dmt-D-Lys-Phe-Phe-Lys-Lys-Pro-Phe-Tle-Leu-OH) that targets single entity opioid and neurotensin pharmacophores. This endomorphin-2-like opioid peptide was introduced as a highly active analgesic because it elicited a strong dose- and time-dependent antinociceptive response when administered centrally and peripherally. Its pain-relieving activity was observed as rapidly as 5 min after drug injection. Such promising results led us to perform further studies, such as determining the resistance to enzymatic degradation, which resulted in obtaining a very stable opioid pharmacore PK20 metabolite. Methods: The synthesis of PK20 and its N-terminal tetrapeptide fragment has been accomplished using solid phase peptide chemistry. The biological stability of peptides has been measured in human serum and analyzed by HPLC/MS. Peptides were pharmacologically characterized in in vitro MOP and DOP receptor binding as well as [35S]GTP?S receptor binding assays. Antinociceptive properties of compounds were measured by in vivo assays in C57Bl6 mice after intravenous or intrathecal applications. Results: Dmt-D-Lys-Phe-Phe-OH (PK20M), an N-terminal tetrapeptide metabolite of the opioid-neurotensin hybrid peptide PK20, is characterized by a long duration of action, as demonstrated by a preserved, long-lasting analgesic effect even 2 h post-injection (average % MPE = 69.33). In rat brain membranes, PK20M efficiently displaced both the MOP and DOP receptor selective radioprobes [3H]DAMGO and [3H]DIDI (pKi of 9.52 and 7.86, respectively) and potently stimulated [35S]GTP?S binding, proving full agonism at both receptor types. In the [35S]GTP?S assay, which measured the agonist-mediated G protein activation, PK20M together with PK20 and Met-enkephalin were potent stimulators of the regulatory G proteins. The relative affinities of PK20M for the ? and receptor subtypes revealed ?-receptor selectivity. Conclusion: The novel MOP receptor selective metabolite has been shown to possess opioid subtype receptor selectivity, high potency, and effective analgesic activities as measured in various bioassays.

AB - Background: Recently, we presented a novel compound (PK20, Dmt-D-Lys-Phe-Phe-Lys-Lys-Pro-Phe-Tle-Leu-OH) that targets single entity opioid and neurotensin pharmacophores. This endomorphin-2-like opioid peptide was introduced as a highly active analgesic because it elicited a strong dose- and time-dependent antinociceptive response when administered centrally and peripherally. Its pain-relieving activity was observed as rapidly as 5 min after drug injection. Such promising results led us to perform further studies, such as determining the resistance to enzymatic degradation, which resulted in obtaining a very stable opioid pharmacore PK20 metabolite. Methods: The synthesis of PK20 and its N-terminal tetrapeptide fragment has been accomplished using solid phase peptide chemistry. The biological stability of peptides has been measured in human serum and analyzed by HPLC/MS. Peptides were pharmacologically characterized in in vitro MOP and DOP receptor binding as well as [35S]GTP?S receptor binding assays. Antinociceptive properties of compounds were measured by in vivo assays in C57Bl6 mice after intravenous or intrathecal applications. Results: Dmt-D-Lys-Phe-Phe-OH (PK20M), an N-terminal tetrapeptide metabolite of the opioid-neurotensin hybrid peptide PK20, is characterized by a long duration of action, as demonstrated by a preserved, long-lasting analgesic effect even 2 h post-injection (average % MPE = 69.33). In rat brain membranes, PK20M efficiently displaced both the MOP and DOP receptor selective radioprobes [3H]DAMGO and [3H]DIDI (pKi of 9.52 and 7.86, respectively) and potently stimulated [35S]GTP?S binding, proving full agonism at both receptor types. In the [35S]GTP?S assay, which measured the agonist-mediated G protein activation, PK20M together with PK20 and Met-enkephalin were potent stimulators of the regulatory G proteins. The relative affinities of PK20M for the ? and receptor subtypes revealed ?-receptor selectivity. Conclusion: The novel MOP receptor selective metabolite has been shown to possess opioid subtype receptor selectivity, high potency, and effective analgesic activities as measured in various bioassays.

KW - [35S]GTP?S

KW - Antinociception

KW - In vivo analgesia

KW - Opioid receptor binding

KW - PK20 metabolite

UR - http://www.scopus.com/inward/record.url?scp=84886489124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886489124&partnerID=8YFLogxK

M3 - Article

VL - 65

SP - 836

EP - 846

JO - Pharmacological Reports

JF - Pharmacological Reports

SN - 1734-1140

IS - 4

ER -